Trevi Therapeutics, Inc. (NASDAQ: TRVI) will report its financial results for the second quarter ended June 30, 2026, and provide a corporate update during a conference call and live audio webcast scheduled for Thursday, August 6, 2026, at 4:30 p.m. ET. The announcement signals the company’s routine disclosure of quarterly performance metrics to investors, offering insights into its operational progress as it advances its investigational therapy pipeline.

Senior management will lead the discussion, focusing on the company’s financial position and strategic developments. Investors can register for the live event through the ‘Investors & News’ section of the company’s website or by visiting ir.trevitherapeutics.com/news-events/events directly. Phone participants will receive unique call-in details via email upon registration. An archived replay of the webcast will remain available on the company’s website for 30 days following the event.

Pipeline and Market Opportunity

Trevi Therapeutics is primarily focused on developing Haduvio (oral nalbuphine extended-release), an investigational therapy targeting chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). The drug acts as a kappa agonist and mu antagonist (KAMA), targeting opioid receptors in the cough reflex arc both centrally and peripherally.

Clinical trials have demonstrated statistically significant reductions in cough frequency with Haduvio, consistent across baseline cough frequencies, alongside improvements in patient-reported outcomes for both IPF-related chronic cough and RCC patients. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.

Unmet Medical Need

Chronic cough represents a significant unmet medical need with no FDA-approved therapies currently available for these specific indications. Approximately 140,000 U.S. patients suffer from IPF, with two-thirds experiencing uncontrolled chronic cough. Additionally, around 228,000 U.S. patients have non-IPF ILD, of whom 50-60% face uncontrolled chronic cough. Patients may cough up to 1,500 times per day, leading to increased morbidity, mortality risks, respiratory hospitalizations, and declined quality of life.

Refractory chronic cough (RCC) affects an estimated 2-3 million U.S. patients. Defined as a persistent cough lasting more than eight weeks despite treatment for underlying conditions such as asthma or gastroesophageal reflux disease, RCC is associated with cough reflex hypersensitivity involving both central and peripheral nervous systems. The condition is highly debilitating, impacting patients physically, psychologically, and socially.

What the Numbers Show

While specific financial figures for Q2 2026 were not disclosed in this announcement, the timing of the earnings release aligns with standard reporting cycles for NASDAQ-listed biopharmaceutical firms. Investors will likely scrutinize cash burn rates and runway given the capital-intensive nature of clinical-stage development. The company intends to propose Haduvio as the trade name for oral nalbuphine ER, though its safety and efficacy have not yet been evaluated by any regulatory authority.

Contact Information

For investor inquiries, Jonathan Carlson can be reached at (203) 654 3286 or IR@trevitx.com . Media contacts should reach out to Rosalia Scampoli at 914-815-1465 or rscampoli@marketcompr.com .

Trevi Therapeutics, Inc. (NASDAQ: TRVI) announced on July 28, 2026, that its senior management will participate in two prominent biotechnology conferences in August 2026. The clinical-stage biopharmaceutical company is developing Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). These presentations offer investors and analysts direct access to leadership regarding the clinical progress and commercial potential of its lead asset.

Conference Schedule

The company detailed the specific dates, locations, and participating executives for each event. Jennifer Good, President and CEO, will represent Trevi at both conferences, while David Hastings, CFO, will join for the Stifel summit.

At the Stifel summit, a fireside chat is scheduled for August 10 from 2:00 p.m. to 2:20 p.m. ET. This in-person session provides a focused opportunity for stakeholder engagement regarding the company’s strategic direction and financial outlook.

Pipeline and Market Opportunity

Haduvio is an investigational therapy designed to act on the cough reflex arc both centrally and peripherally as a kappa agonist and mu antagonist (KAMA). It targets opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. In clinical trials, Haduvio demonstrated a statistically significant reduction in cough frequency, consistent across baseline cough frequencies, and showed improvements in patient-reported outcomes for both IPF-related chronic cough and RCC patients.

Chronic cough in patients with IPF and non-IPF ILD represents a condition with high unmet need and no FDA-approved therapies. Approximately 140,000 U.S. patients have IPF, with two-thirds facing uncontrolled chronic cough. Additionally, roughly 228,000 U.S. patients have non-IPF ILD, with 50–60% experiencing uncontrolled chronic cough. Patients may cough up to 1,500 times per day, leading to higher risks of morbidity, mortality, respiratory hospitalizations, and declined quality of life.

Refractory chronic cough (RCC) also lacks FDA-approved therapies. Defined as a persistent cough lasting more than 8 weeks despite treatment for underlying conditions such as asthma or gastroesophageal reflux disease, RCC affects approximately 2–3 million U.S. patients. The condition is associated with cough reflex hypersensitivity involving both central and peripheral nervous systems, causing significant physical, psychological, and social impacts.

Regulatory Status

Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. The safety and efficacy of the therapy have not yet been evaluated by any regulatory authority. For further information, investors are directed to www.TreviTherapeutics.com .